Paul Devakar Yesudian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul Devakar Yesudian has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Lucy Smith
Department of Dermatology, Wrexham Maelor Hospital , Wrexham , UK
2 shared publications - Abhishek Sharma
Department of Global Health Boston University School of Public Health Boston MA USA
1 shared publication - Alina M Constantin
British Association of Dermatologists , Willan House, London
1 shared publication Amaani B Hussain
Royal Victoria Infirmary , Newcastle upon Tyne
1 shared publicationBrian Kirby
St Vincent’s University Hospital , Dublin
1 shared publicationCatriona Maybury
St George's Healthcare NHS Trust , London
1 shared publication
Latest Publications
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (9) , 1725-1727
A cross-sectional survey of stakeholders to inform the update of the British Association of Dermatologists guidelines for the safe and effective prescribing of methotrexate in dermatology
Stakeholder engagement is best practice for guideline development and implementation. We therefore aimed to gather evidence in the form of a cross-sectional survey of patients’ and healthcare professionals’ research priorities for the British Association of Dermatologists methotrexate guideline.
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (9) , 1725-1727
A cross-sectional survey of stakeholders to inform the update of the British Association of Dermatologists guidelines for the safe and effective prescribing of methotrexate in dermatology
Stakeholder engagement is best practice for guideline development and implementation. We therefore aimed to gather evidence in the form of a cross-sectional survey of patients’ and healthcare professionals’ research priorities for the British Association of Dermatologists methotrexate guideline.
- 14 May 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 696-705
Chromoblastomycosis: a contemporary review of a neglected disease
Of the melanized fungal infections affecting humans, chromoblastomycosis (CBM) remains the most prevalent. Also known as chromomycosis, this condition typically manifests as insidious-onset cutaneous lesions that eventually progress to cause physical disability. CBM is considered a neglected tropical disease (NTD) by the World Health Organization because of its significant impact on populations living in poverty throughout tropical regions, the paucity of research, and the opportunity to improve treatment and prevention. In many individuals, the diagnosis is delayed and this is thought to be because of the multitude of clinical mimics and the lack of general awareness. Furthermore, the subcutaneous invasion of this infection creates therapeutic challenges. A small number of studies have identified partially successful treatments and potential pharmacological targets. In this article we present an updated review of this condition to give a contemporary perspective on a neglected disease.
- 14 May 2025
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (5) , 696-705
Chromoblastomycosis: a contemporary review of a neglected disease
Of the melanized fungal infections affecting humans, chromoblastomycosis (CBM) remains the most prevalent. Also known as chromomycosis, this condition typically manifests as insidious-onset cutaneous lesions that eventually progress to cause physical disability. CBM is considered a neglected tropical disease (NTD) by the World Health Organization because of its significant impact on populations living in poverty throughout tropical regions, the paucity of research, and the opportunity to improve treatment and prevention. In many individuals, the diagnosis is delayed and this is thought to be because of the multitude of clinical mimics and the lack of general awareness. Furthermore, the subcutaneous invasion of this infection creates therapeutic challenges. A small number of studies have identified partially successful treatments and potential pharmacological targets. In this article we present an updated review of this condition to give a contemporary perspective on a neglected disease.
- 26 March 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (9) , 1066-1067
Dermatology clinic attendance rates: does the content of an SMS reminder make a difference?
This is a study assessing the impact of SMS reminders on ‘did not attend’ rates, including the effect of an attempt to ‘nudge’ patients by highlighting the financial burden to the NHS of a missed appointment in an effort to motivate them to attend their outpatient clinic appointment.
- 26 March 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (9) , 1066-1067
Dermatology clinic attendance rates: does the content of an SMS reminder make a difference?
This is a study assessing the impact of SMS reminders on ‘did not attend’ rates, including the effect of an attempt to ‘nudge’ patients by highlighting the financial burden to the NHS of a missed appointment in an effort to motivate them to attend their outpatient clinic appointment.
- 9 December 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (4) , 386-387
Do hypoallergenic skincare products contain fewer potential contact allergens?
Personal care products (PCPs) commonly cause allergic contact dermatitis (ACD). Skincare companies often market their products as ‘hypoallergenic’; however, this term is not regulated by industry standards. To determine whether PCPs marketed as hypoallergenic are truly less likely to precipitate ACD, we conducted a study of ingredients found in ‘hypoallergenic PCPs’ from two major UK retailers in 2022. Of 208 products meeting the inclusion criteria, 153 (73.6%) contained at least 1 allergen or related chemical from the British Society for Cutaneous Allergy baseline series, 21 (10.1%) had 2 potential allergens and 4 PCPs (1.9%) had 3 allergens. Cetearyl alcohol was the most common allergen identified in leave-on PCPs and parabens in rinse-off products; fragrance was the most frequent related chemical found in 85 PCPs (40.1%). A high prevalence of common allergens was found in hypoallergenic PCPs, suggesting that dermatologists and consumers should be cautious of product ingredients.
- 9 December 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 49 (4) , 386-387
Do hypoallergenic skincare products contain fewer potential contact allergens?
Personal care products (PCPs) commonly cause allergic contact dermatitis (ACD). Skincare companies often market their products as ‘hypoallergenic’; however, this term is not regulated by industry standards. To determine whether PCPs marketed as hypoallergenic are truly less likely to precipitate ACD, we conducted a study of ingredients found in ‘hypoallergenic PCPs’ from two major UK retailers in 2022. Of 208 products meeting the inclusion criteria, 153 (73.6%) contained at least 1 allergen or related chemical from the British Society for Cutaneous Allergy baseline series, 21 (10.1%) had 2 potential allergens and 4 PCPs (1.9%) had 3 allergens. Cetearyl alcohol was the most common allergen identified in leave-on PCPs and parabens in rinse-off products; fragrance was the most frequent related chemical found in 85 PCPs (40.1%). A high prevalence of common allergens was found in hypoallergenic PCPs, suggesting that dermatologists and consumers should be cautious of product ingredients.
- Open Access
- 14 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (3) , 290-292
IgG4-related skin disease responsive to thalidomide
IgG4-related disease is a rare, immune-mediated disorder characterized by tissue infiltration with IgG4+ plasma cells, along with elevated serum IgG4. The hallmark is distinctive histological fibroinflammatory change associated with abundant IgG4+ plasma cell deposition.1 Clinically and radiologically, mass-forming lesions are observed at the affected areas, whilst histologically there is a dense lymphoplasmacytic infiltrate with storiform fibrosis, obliterative phlebitis and mild to moderate tissue eosinophilia. The cutaneous disease may occur in isolation or with other system involvement, most frequently the pancreas, salivary glands and lacrimal glands; however, the biliary tree, mediastinum, kidney, pituitary gland and orbits can also be affected. We present a case of IgG4-related skin disease (IgG4-RSD) responsive to thalidomide.
- 14 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (3) , 290-292
Open AccessIgG4-related skin disease responsive to thalidomide
IgG4-related disease is a rare, immune-mediated disorder characterized by tissue infiltration with IgG4+ plasma cells, along with elevated serum IgG4. The hallmark is distinctive histological fibroinflammatory change associated with abundant IgG4+ plasma cell deposition.1 Clinically and radiologically, mass-forming lesions are observed at the affected areas, whilst histologically there is a dense lymphoplasmacytic infiltrate with storiform fibrosis, obliterative phlebitis and mild to moderate tissue eosinophilia. The cutaneous disease may occur in isolation or with other system involvement, most frequently the pancreas, salivary glands and lacrimal glands; however, the biliary tree, mediastinum, kidney, pituitary gland and orbits can also be affected. We present a case of IgG4-related skin disease (IgG4-RSD) responsive to thalidomide.
- Open Access
- 1 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (11) , 2072-2073
Understanding psoriasis: the development of the immune pathogenesis
Click here for the corresponding questions to this CME article.
- 1 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (11) , 2072-2073
Open AccessUnderstanding psoriasis: the development of the immune pathogenesis
Click here for the corresponding questions to this CME article.
- Open Access
- 20 October 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (2) , 128-129
The Dermatology Life Quality Index and sleep: it’s time to wake up
‘You lack the season of all natures, sleep.’ William Shakespeare The Dermatology Life Quality Index (DLQI) is a questionnaire devised by Finlay and Khan in 1992
- 20 October 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (2) , 128-129
Open AccessThe Dermatology Life Quality Index and sleep: it’s time to wake up
‘You lack the season of all natures, sleep.’ William Shakespeare The Dermatology Life Quality Index (DLQI) is a questionnaire devised by Finlay and Khan in 1992
- 22 July 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (1) , 9-15
Nail changes in diabetes
Diabetes is a common condition that is increasing in incidence all over the world. Even though the skin manifestations of this condition are well described, there is scant literature of its nail changes. In this review, we allude to the various clinical features of nail changes in those with diabetes. They can be broadly divided into infections, vascular changes, neuropathic manifestations, and miscellaneous changes. There is no pathognomonic nail alteration, but it is important to be aware of the potential nail manifestations in diabetes as it facilitates investigations and thereby early diagnosis of diabetes, resulting in holistic management of the patient.
- 22 July 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (1) , 9-15
Nail changes in diabetes
Diabetes is a common condition that is increasing in incidence all over the world. Even though the skin manifestations of this condition are well described, there is scant literature of its nail changes. In this review, we allude to the various clinical features of nail changes in those with diabetes. They can be broadly divided into infections, vascular changes, neuropathic manifestations, and miscellaneous changes. There is no pathognomonic nail alteration, but it is important to be aware of the potential nail manifestations in diabetes as it facilitates investigations and thereby early diagnosis of diabetes, resulting in holistic management of the patient.
- Open Access
- 25 November 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (11) , e225971
Double trouble: ciclosporin–simvastatin coinduced rhabdomyolysis
A 73-year-old woman presented with an acute exacerbation of her long-standing psoriasis. Ciclosporin was commenced due to the severity of her symptoms resulting in remission within 2 weeks. Full blood count, urea and electrolytes following initiation of treatment were unremarkable, although she complained of muscle aches, which was attributed to her known multiple sclerosis. Three weeks later she was admitted to the hospital with diarrhoea and vomiting. Repeat blood tests revealed raised creatinine (528 μmol/L (normal range (NR) n=45–84 μmol/L)), urea (32.6 mmol/L (NR 2.5–7.8 mmol/L)) and creatine kinase (6792 IU/L (NR 25–200 IU/L)) levels and reduced estimated glomerular filtration rate of 7. A diagnosis of acute kidney injury secondary to rhabdomyolysis was made due to an interaction between ciclosporin and simvastatin, precipitated by the dehydration from gastroenteritis. Haemofiltration was required to stabilise her renal function and she made a complete recovery.
- 25 November 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (11) , e225971
Open AccessDouble trouble: ciclosporin–simvastatin coinduced rhabdomyolysis
A 73-year-old woman presented with an acute exacerbation of her long-standing psoriasis. Ciclosporin was commenced due to the severity of her symptoms resulting in remission within 2 weeks. Full blood count, urea and electrolytes following initiation of treatment were unremarkable, although she complained of muscle aches, which was attributed to her known multiple sclerosis. Three weeks later she was admitted to the hospital with diarrhoea and vomiting. Repeat blood tests revealed raised creatinine (528 μmol/L (normal range (NR) n=45–84 μmol/L)), urea (32.6 mmol/L (NR 2.5–7.8 mmol/L)) and creatine kinase (6792 IU/L (NR 25–200 IU/L)) levels and reduced estimated glomerular filtration rate of 7. A diagnosis of acute kidney injury secondary to rhabdomyolysis was made due to an interaction between ciclosporin and simvastatin, precipitated by the dehydration from gastroenteritis. Haemofiltration was required to stabilise her renal function and she made a complete recovery.